How would you approach frontline treatment for a metastatic non-squamous NSCLC patient with MET amplification and a concurrent KRAS mutation?

Topics: Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University

Answer from: Medical Oncologist at Academic Institution

There are a couple of components to this question: first, what is the role of TKI therapy in MET amplified lung cancer, and second, what is a clinician to do when there are more than one "driver" mutations (ie KRAS and MET amp in this case)? Regarding the first question, this is somewhat timely in t...

Related Questions